Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Novo Nordisk will remain the leading company in the metabolism sector in 2014 based on its broad insulin portfolio, while Merck will establish itself as one of the top five metabolism players in the same year as a result of sales of first-to-market DPP-IV inhibitor Januvia.

The new report entitled Commercial Outlook for Metabolism: 2003-2014 also finds that the withdrawal of Sanofi-Aventis' Acomplia in Europe and the dearth of agents in late-stage development leave a significant gap in the obesity market. Poor efficacy and safety profiles of currently approved agents have combined with an unfavorable reimbursement climate to limit sales of obesity agents to date.

"Within the metabolism therapeutic area, the obesity drug market has yet to realize its potential," said Ben Duncan, associate analyst at Decision Resources. "The few late-stage candidates in development for obesity all belong to smaller pharmaceutical and biotech companies, and therefore if they can demonstrate improved efficacy over currently available therapies, look for larger pharmaceutical companies to partner with, or acquire, these organizations."

The report is the first of its kind from Decision Resources, outlining the entire drug market for diabetes, obesity, growth hormones and agents to treat a variety of niche endocrinology indications. Each drug class is thoroughly dissected with robust data on major brands, supporting brands, late and early stage R&D candidates. The 155 page report also includes the therapy area rankings by company from 2003-2014, the sales by class from 2003-2014 and key events within the metabolism market.

In addition to the report, Commercial Outlook for Metabolism: 2003-2014 will include an interactive forecast model for metabolism as well as a unique slide deck featuring analysis on the metabolic franchises of the top 20 pharmaceutical companies.

About Commercial Outlook for Metabolism: 2003-2014

Commercial Outlook for Metabolism: 2003-2014 is part of the Pharmaview franchise from Decision Resources. Offering top-down sales numbers, complete overviews of all major drugs on the market and in late and early-stage development, this report is a must-have for any biopharmaceutical company in, or looking to break into, the metabolism sector or any company partnering with or selling into a drug company currently in the metabolism sector.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Heather Hilty   Decision Resources   781-296-2536   hhilty@dresources.com    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Heather Hilty of Decision Resources, +1-781-296-2536,
hhilty@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Most Important Factors Driving Usage of Antibiotics in the ICU Setting are Availability in Intravenous Formulation, Activity Against Key Gram Negative Pathogens, Drug Interactions and Bactericidal Activity

View Now